Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bimatoprost + latanoprost (Allergan)
- Development stage
- Unknown
- Lead developer
- Allergan
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Lumigan PF + latanoprost refers to the use or comparison of two prostaglandin analog ophthalmic solutions: preservative-free bimatoprost 0.03% (Lumigan PF) and benzalkonium chloride (BAK)-preserved latanoprost 0.005% (Xalatan). Both agents are indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. They function as agonists at the prostaglandin F (FP) receptor, which enhances the uveoscleral outflow of aqueous humor. In clinical research, specifically a study conducted by National Taiwan University Hospital, these two formulations were compared to evaluate the impact of the BAK preservative on ocular surface disease (OSD), testing the hypothesis that the preservative-free bimatoprost formulation causes less ocular surface damage than the preserved latanoprost formulation.
- Brand names
- Xalatan
- Other names
- Lumigan PF + latanoprostpreservative-free bimatoprost + latanoprost
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on bimatoprost + latanoprost (Allergan).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bimatoprost + latanoprost (Allergan).